We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
301
PUT
Rocket Pharmaceuticals
RCKT
$343M
– –
-125
Closed -$305K
REGN icon
302
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-202
Closed -$7.42M
REGN icon
303
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-162,517
Closed -$59.7M
REGN icon
304
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-2,198
Closed -$80.7M
RGNX icon
305
Regenxbio
RGNX
$616M
– –
-48,400
Closed -$898K
RIGL icon
306
Rigel Pharmaceuticals
RIGL
$723M
– –
-1,235
Closed -$29K
SGMO
307
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-63,204
Closed -$254K
SLS icon
308
PUT
SELLAS Life Sciences
SLS
$1.99B
– –
-1
Closed -$164K
SRPT icon
309
Sarepta Therapeutics
SRPT
$1.64B
– –
-2,014,787
Closed -$62.4M
SRPT icon
310
PUT
Sarepta Therapeutics
SRPT
$1.64B
– –
-19,251
Closed -$52.8M
TENX icon
311
CALL
Tenax Therapeutics
TENX
$393M
– –
0
– -$2.39M
TENX icon
312
PUT
Tenax Therapeutics
TENX
$393M
– –
0
– -$33K
TEVA icon
313
CALL
Teva Pharmaceuticals
TEVA
$40.4B
– –
-8,638
Closed -$31.3M
TVTX icon
314
CALL
Travere Therapeutics
TVTX
$5.17B
– –
-4,798
Closed -$9.08M
TVTX icon
315
PUT
Travere Therapeutics
TVTX
$5.17B
– –
-408
Closed -$772K
TXMD icon
316
TherapeuticsMD
TXMD
$23.8M
– –
-499
Closed -$154K
TXMD icon
317
PUT
TherapeuticsMD
TXMD
$23.8M
– –
-12
Closed -$338K
VCYT icon
318
Veracyte
VCYT
$4.45B
– –
-193,999
Closed -$1.5M
VNDA icon
319
CALL
Vanda Pharmaceuticals
VNDA
$304M
– –
-503
Closed -$802K
VTRS icon
320
CALL
Viatris
VTRS
$20.8B
– –
-4,162
Closed -$15.9M
XBI icon
321
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-11,700
Closed -$693K
XTLB
322
XTL Biopharmaceuticals
XTLB
$7.27M
– –
-36,207
Closed -$434K
XYLO
323
DELISTED
Xylo Technologies
XYLO
– –
-55
Closed -$50K
CSCI
324
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-4,006
Closed -$1.18M
IRD
325
Opus Genetics
IRD
$287M
– –
-15,264
Closed -$1.04M
11 12
13
14 15

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.